Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease

被引：30

作者：

Sonino N. ^{[1
]}

Fava G.A. ^{[1
]}

Fallo F. ^{[1
]}

Franceschetto A. ^{[1
]}

Belluardo P. ^{[1
]}

Boscaro M. ^{[1
]}

机构：

[1] Dept. of Medical/Surgical Sciences, Division of Endocrinology, University of Padova, 35128 Padova

来源：

Pituitary | 2000年 / 3卷 / 2期

关键词：

Cushing's disease; Ketanserin; Ritanserin; Serotonin;

D O I：

10.1023/A:1009986822146

中图分类号：

学科分类号：

摘要：

Central serotonergic regulation could have a role in the course of pituitary-dependent Cushing's disease. We studied the effects of ritanserin and ketanserin, two related selective 5HT2 receptor antagonists, in 11 patients with Cushing's disease. Treatment lasted from 1 month to 1 year (up to 4 years in one patient). Daily doses were 10-15 mg for ritanserin, and 40-80 mg for ketanserin. Since the two drugs share the same mechanism of action and no qualitative or quantitative differences in response to their administration were observed, the results were pooled together. Patients were assessed by clinical and hormonal evaluation. Urinary cortisol and ACTH were considered the parameters of interest. Short-term response: after 1 month, there was a significant decrease of urinary cortisol from 781 (160) to 331 (215) nmol/d (P < 0.02) while ACTH was 9.8 (1.5) pmol/L baseline and again 8.8 (2.2) pmol/L at 1 month (P = NS). For 9 patients, hormonal parameters were available after 1 week of treatment. In this case, also ACTH levels were significantly decreased (from 9.6 (1.7) to 5.2 (1.3) pmol/L; P < 0.01) together with urinary cortisol (from 781 (194) to 372 (165) nmol/d; P < 0.01). Long-term response: in 3 patients, hormonal parameters failed to respond to serotonin receptor antagonists, which were thus discontinued. An improvement was recorded in the remaining 8 patients, that was prolonged in 3, and transient in 5. In 3 of these latter patients, a marked increase of ACTH was observed before treatment discontinuation. Ketanserin was given to 2 patients with Nelson's syndrome, with only transient ACTH decrease in one, and no changes in ACTH response to CRH after 1 month treatment in both cases. An inhibitory effect of ritanserin and ketanserin on ACTH and cortisol production in Cushing's disease appeared to be limited both in terms of duration of response and number of patients with a satisfactory outcome. However, the results may provide a better understanding of serotonergic modulation in Cushing's disease and lead to therapeutic developments.

引用

页码：55 / 59

页数：4

共 39 条

[1]

Krieger D.T., Amorosa L., Limick F., Cyproheptadine-induced remission of Cushing's disease, N Engl J Med, 293, pp. 893-896, (1975)

[2]

Miller J.W., Crapo L., The medical treatment of Cushing's syndrome, Endocrol Rev, 14, pp. 443-458, (1993)

[3]

Sonino N., Boscaro M., Medical therapy for Cushing's disease, Endocrinol Metab Clin North Am, 28, pp. 211-222, (1999)

[4]

Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P.A., International union pharmacology classification of receptors for 5-hydroxytryptamine (serotonin), Pharmacol Rev, 46, pp. 157-203, (1994)

[5]

Grossman A., What is the cause of Cushing's disease?, Clin Endocrinol, 36, pp. 451-452, (1992)

[6]

Biller M.K., Pathogenesis of pituitary Cushing's syndrome, Endocrinol Metab Clin North Am, 23, pp. 547-553, (1994)

[7]

Leysen J.E., Gommeren W., van Gompel P., Wynants J., Janssen P.F.M., Laduron P.M., Receptor-binding properties in vitro and in vivo of ritanserin, Mol Pharmacol, 27, pp. 600-611, (1985)

[8]

Awouters F., Niemegeers C.J.E., Megens A.A.H.P., Meert T.F., Janssen P.A.J., Pharmacological profile of ritanserin: A very specific central serotonin S2-antagonist, Drug Dev Res, 15, pp. 61-73, (1988)

[9]

Kristiansen K., Dahl S.G., Molecular modeling of serotonin, ketanserin, ritanserin and their 5HT2C receptor interactions, Eur J Pharmacol, 306, pp. 195-210, (1996)

[10]

Stefanski R., Goldberg S.R., Serotonin 5HT2 receptor antagonists. Potential in the treatment of psychiatric disorders, CNS Drugs, 7, pp. 308-409, (1997)

← 1 2 3 4 →